Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain

What's New

Introductions to the latest additions to the AMS website are shown here.

Members should log in to see the Members's only content on this page. 

  • Heavy Menstrual Bleeding Clinical Care Standard launched
    7 December 2017:  Women to benefit from first national treatment standard for heavy periods  The first nationally agreed standard of care for women experiencing heavy menstrual bleeding says women should be offered less invasive treatments before considering a hysterectomy – a major op... Read more.
  • Oestrogen patch update - supply returned
    30 November 2017:  Novartis has advised that the company has both received and released stock for supply locally of the following lines; ESTALIS CONT 50+140MCG  ESTALIS SEQ 50MCG/50+ 140MCG  ESTALIS SEQ 50MCG/50+ 250MCG As a result the only remaining HRT line now still u... Read more.
  • Women's memory may benefit from hormone replacement therapy
    A type of hormone replacement therapy may protect memory for some women, according to an American study. The research findings are the latest to indicate that hormone replacement therapy may have some benefits, deepening scientific discussions about the pros and cons of the menopausal treatment. "... Read more.
  • Discontinuing hormone therapy increases risk of cardiac and stroke death
    Hormone therapy (HT) continues to be a hotly debated topic. The benefits of estrogen to the heart, however, appear to be universally accepted. A European study demonstrates that the risk of cardiac and stroke death actually increases in the first year after discontinuation of HT. Since publication ... Read more.
  • Postmenopausal obesity redefined
    BMI may not be valid measure of obesity status in older adults There is no doubt the prevalence of obesity has increased significantly across all age groups, creating greater health risks. What exactly constitutes obesity, however, is subject to debate, especially for postmenopausal women who ... Read more.
  • Prasterone (Intrarosa) for Dyspareunia
    From the Medical Letter The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA) (Table 1). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the ... Read more.
  • Bioidentical Hormones - risks revisited
    The October issue of Endocrine news (1) carries an article that once again tackles the complexity of bioidentical hormones. The freelance US writer highlights the confusion surrounding "bioidentical hormones" and more specifically the compounded formulations that are promoted as "natural". Th... Read more.
  • Cognitive Concerns
    Dr Victor Henderson Past President, The North American Menopause Society Professor, Health Research and Policy and Neurology and Neurological Sciences Stanford University Director, Alzheimer’s Disease Research Center Stanford, CA Dr Hendersen discusses cognitive changes during menopause and when t... Read more.
  • Why some women are more likely to feel depressed
    Study links duration of estrogen exposure with increased vulnerability to depression: Longer exposure to estrogen shown to provide protection It's no secret that the risk of depression increases for women when their hormones are fluctuating. Especially vulnerable times include the menopause transit... Read more.
  • Early menopause is independently linked to an increased risk of developing type 2 diabetes
    Women with early or normal onset menopause are at a higher risk of developing type 2 diabetes than those with late onset menopause, concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes). Previous research (by the same authors of this ne... Read more.
  • Eating more vegetable protein may protect against early menopause
    Study shows modest but significant lower risk Results of a new study from epidemiologists at the University of Massachusetts Amherst and Harvard T.H. Chan School of Public Health suggest that long-term, high intake of vegetable protein from such foods as whole grains, soy and tofu, may protect wome... Read more.
  • Knowledge and attitudes of health professionals regarding menopausal hormone therapies
    Objective:  To evaluate the knowledge and attitudes of Australian health professionals (HPs) including general practitioners (GPs), gynecologists and endocrinologists, to menopausal hormone therapy (MHT). Methods:  Participants were recruited from medical societies/colleges and a nation... Read more.
  • Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis
    This review in 2016 of 62 studies suggests that some plant-based therapies are associated with modest reductions in the frequency of hot flushes and vaginal dryness but no significant reduction in night sweats.  Abstract Importance: Between 40% and 50% of women in Western countries use com... Read more.
  • NAMS 2017 position statement updates guidelines for hormone therapy use
    A new position statement on the use of hormone therapy (HT) for menopausal and postmenopausal women from The North American Menopause Society (NAMS) has been published online today in the Society's journal, Menopause. "The use of hormone therapy continues to be one of the most controversial and deba... Read more.
  • Oestrogen patch shortage information
    20 April 2017:  Fairfax through The Sydney Morning Herald and The Age, has published a story about the current shortage of oestrogen patches, a hormone replacement treatment used to manage menopausal symptoms. With so many questions being raised about the shortage, Jean Hailes Medical Di... Read more.
  • Perimenopausal and Postmenopausal Bleeding
    Dr. Steven Goldstein Past President of NAMS, Professor of Obstetrics and Gynecology at New York University School of Medicine, and Co-Director of the Bone Densitometry and Body Composition unit at the NYU Langone Medical Center. Dr Goldstein discusses discusses vaginal ultrasound for postmenopause... Read more.
  • AMS Guide to Equivalent MHT/HRT Doses New Zealand only
    This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different MHT/HRT products available in New Zealand in March 2017. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to help physicians change their patient... Read more.
  • Langer's insights on the WHI study: unbiased evaluation and behind the scene facts
    27 March, 2017:  I urge everyone carefully to read Robert Langer's article in the April issue of Climacteric [1]. Members can download the paper from the IMS website. Langer was one of the chief investigators of the WHI project, both clinician and epidemiologist, who was able to bring not only... Read more.
  • Cognitive aging in midlife women: is it real?
    20 March, 2017:  Cognitive aging has become an important issue because of increased life expectancy in women. Cognitive complaints are common during midlife, as part of the climacteric syndrome. By using data from a longitudinal observational study in 2124 participants from the Study of Women'... Read more.
  • A Clinician's Guide to Bone Drug Holidays
    Dr Michael McClung NAMS Board Member and Founding Director of the Oregon Osteoporosis Center in Portland, Oregon. Dr McClung discusses the right timing for drug holidays from bisphosphonates for women at low risk and as well as follow-up procedures. He discusses those who should not consider a dru... Read more.

Print Email


Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain